Focus: Cancer vaccines based on mRNA advance, despite US cuts
A personalized mRNA cancer vaccine, when administered alongside the immunotherapy drug pembrolizumab, reduced the risk of melanoma recurrence or death by 49% over five years, according to findings presented at ... Read More